Table 3.
Sleep adequacy, colon cancer recurrence, and mortality.
| Sleep duration adequacy | |||
|---|---|---|---|
| Adequate | Not adequate | P value | |
| Disease-free survival | |||
| # Event/at risk | 121/765 | 60/368 | |
| Age- and caffeine intake-adjusted only, HR (95% CI) | Ref | 1.14 (0.84–1.57) | 0.40 |
| Multivariable-adjusted, HR (95% CI)a | Ref | 1.26 (0.91–1.73) | 0.16 |
| Multivariable-adjusted, HR (95% CI)b | Ref | 1.27 (0.92–1.76) | 0.15 |
| Overall survival | |||
| # Event/at risk | 59/765 | 30/368 | |
| Age- and caffeine intake-adjusted only, HR (95% CI) | Ref | 1.33 (0.85–2.08) | 0.22 |
| Multivariable-adjusted, HR (95% CI)a | Ref | 1.45 (0.92–2.29) | 0.11 |
| Multivariable-adjusted, HR (95% CI)b | Ref | 1.46 (0.92–2.31) | 0.11 |
aMultivariable-adjusted model adjusted for age, caffeine intake, sex, T-stage, N-stage, ECOG performance status, and alcohol consumption.
bMultivariable-adjusted model adjusted for age, caffeine intake, sex, T-stage, N-stage, ECOG performance status, alcohol consumption, physical activity, BMI, smoking status, any neuropathy or grade 3+ toxicities during follow-up, relative dose intensities of fluorouracil and oxaliplatin, treatment arm, and use of pain relief medications.